Share on StockTwits
 

Shares of Omnicell (NASDAQ:OMCL) hit a new 52-week high during trading on Thursday, StockRatingsNetwork reports. The stock traded as high as $25.94 and last traded at $25.75, with a volume of 137,237 shares trading hands. The stock had previously closed at $25.24.

Several analysts have recently commented on the stock. Analysts at B. Riley upgraded shares of Omnicell from a “neutral” rating to a “buy” rating in a research note to investors on Friday, December 13th. They now have a $28.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Omnicell from a “neutral” rating to an “underperform” rating in a research note to investors on Friday, November 22nd. They now have a $22.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Omnicell from $21.00 to $24.00 in a research note to investors on Friday, November 1st. They now have a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $24.60.

Omnicell has a 52 week low of $14.68 and a 52 week high of $25.94. The stock’s 50-day moving average is $24.50 and its 200-day moving average is $23.05. The company has a market cap of $915.3 million and a P/E ratio of 39.44.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.31 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.28 by $0.03. The company had revenue of $94.03 million for the quarter, compared to the consensus estimate of $94.96 million. During the same quarter last year, the company posted $0.29 earnings per share. Omnicell’s revenue was up 11.5% compared to the same quarter last year. Analysts expect that Omnicell will post $1.07 EPS for the current fiscal year.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.